This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| follicular lymphoma | |
|---|---|
| Name | Follicular lymphoma |
| Field | Hematology, Oncology |
| Symptoms | Painless lymphadenopathy, fatigue, B symptoms |
| Complications | Transformation to diffuse large B-cell lymphoma, cytopenias, infections |
| Onset | Middle age to older adults |
| Duration | Chronic, indolent |
| Causes | B-cell neoplasm with t(14;18)(q32;q21) in many cases |
| Risks | Age, immune dysregulation, family history |
| Diagnosis | Lymph node biopsy, immunophenotyping, cytogenetics |
| Differential | Diffuse large B-cell lymphoma, mantle cell lymphoma, reactive follicular hyperplasia |
| Treatment | Observation, rituximab, chemoimmunotherapy, radiotherapy, stem cell transplant |
follicular lymphoma Follicular lymphoma is an indolent B-cell non-Hodgkin lymphoma characterized by neoplastic germinal center B cells that form follicle-like nodules in lymphoid tissues. It commonly presents with generalized, painless lymphadenopathy and a relapsing–remitting clinical course, with potential transformation to a more aggressive lymphoma. Management balances observation and active therapy using immunotherapy, chemotherapy, targeted agents, and hematopoietic transplantation.
Patients typically present with painless enlargement of lymph nodes in the cervical, axillary, or inguinal regions and may report fatigue, night sweats, and unintentional weight loss. Advanced disease can cause splenomegaly, hepatomegaly, cytopenias from bone marrow involvement, and extranodal manifestations such as gastrointestinal or pulmonary lesions. Constitutional B symptoms may appear and raise concern for transformation, similar to presentations seen in cases managed at major centers like Mayo Clinic, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center.
The neoplasm arises from germinal center B cells with hallmark chromosomal translocation t(14;18)(q32;q21) resulting in overexpression of the anti-apoptotic protein BCL2, a feature first reported in cytogenetic studies associated with the work of researchers in institutions such as National Cancer Institute and Fred Hutchinson Cancer Research Center. Common immunophenotypic markers include CD20, CD10, BCL6 positivity, and surface immunoglobulin expression. Additional recurrent alterations involve mutations in genes regulating chromatin remodeling and epigenetic control, including CREBBP, EZH2, KMT2D, and EP300; these discoveries have been advanced by consortia like The Cancer Genome Atlas and groups at Institute of Cancer Research. Clonal evolution and microenvironmental interactions with follicular helper T cells, follicular dendritic cells, and cytokine networks contribute to indolence and eventual progression, paralleling insights from studies at Dana-Farber Cancer Institute and Broad Institute.
Definitive diagnosis relies on excisional lymph node biopsy with histopathology demonstrating neoplastic follicles that lack normal mantle zones, graded by centroblast count. Immunohistochemistry and flow cytometry demonstrating CD20+, CD10+, BCL2+ phenotypes distinguish it from reactive processes; molecular testing for t(14;18) by FISH or PCR and next-generation sequencing panels assist classification. Imaging with computed tomography and positron emission tomography, commonly performed at centers such as Johns Hopkins Hospital and Cleveland Clinic, evaluates extent of disease; bone marrow biopsy is often performed to assess marrow involvement. Differential diagnosis includes diffuse large B-cell lymphoma, mantle cell lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma, with guidance drawn from pathology protocols at institutions like American Society of Hematology.
Staging follows the Ann Arbor system, refined by prognostic indices including the Follicular Lymphoma International Prognostic Index (FLIPI, FLIPI2) developed through international collaborations including European Organisation for Research and Treatment of Cancer and International Prognostic Factors Project. Risk features include age, stage, hemoglobin, number of nodal areas, and serum LDH; these variables stratify patients into distinct survival groups. Median survival historically exceeded a decade in many cohorts treated at centers such as Royal Marsden Hospital and Vall d'Hebron University Hospital, though risk of histologic transformation to diffuse large B-cell lymphoma significantly worsens prognosis. Biomarkers and minimal residual disease assessments from networks like European Hematology Association inform relapse risk.
Management ranges from active surveillance for asymptomatic, low-burden disease to rituximab-based chemoimmunotherapy (e.g., R-CHOP, R-CVP, bendamustine-rituximab) informed by trials from groups such as National Comprehensive Cancer Network, European Society for Medical Oncology, and cooperative groups including Alliance for Clinical Trials in Oncology. Localized early-stage disease may be treated with involved-site radiotherapy, as practiced at Royal Free Hospital and Guy's and St Thomas' NHS Foundation Trust. Relapsed or refractory disease options include lenalidomide plus rituximab, PI3K inhibitors developed by pharmaceutical collaborations with centers like Dana-Farber Cancer Institute, and EZH2 inhibitors for mutated cases based on trials led by MD Anderson Cancer Center. Autologous and allogeneic hematopoietic stem cell transplantation remain considerations for select high-risk patients; CAR T-cell therapy, developed through work at University of Pennsylvania and Seattle Cancer Care Alliance, is emerging for transformed or refractory disease. Supportive care and infection prophylaxis follow guidelines from organizations such as Centers for Disease Control and Prevention.
Follicular lymphoma accounts for a substantial proportion of adult non-Hodgkin lymphoma in Western populations, with incidence patterns reported by cancer registries including Surveillance, Epidemiology, and End Results Program and European Cancer Registry. It predominantly affects middle-aged and older adults, with a slight female predominance in some series reported by institutions like Karolinska Institute and University of Oxford. Geographic variations show lower incidence in East Asian registries such as National Cancer Center Japan compared with Western registries, implicating environmental and genetic modifiers researched by groups at Peking University and Seoul National University Hospital.
Originally described through histologic classification efforts led by pathologists at institutions such as St Bartholomew's Hospital and Mayo Clinic in the mid-20th century, the molecular hallmark t(14;18) was elucidated in cytogenetic studies at laboratories like Cold Spring Harbor Laboratory and Institut Gustave Roussy. Subsequent development of monoclonal anti-CD20 antibody therapy revolutionized management following pivotal trials at University of Leicester and University College London. Ongoing research includes genomic profiling by Wellcome Trust Sanger Institute and immunotherapy trials coordinated by international consortia like European Society for Medical Oncology and American Society of Hematology, investigating targeted agents, bispecific antibodies, and personalized cellular therapies with contributions from Novartis, Gilead Sciences, and academic centers including Memorial Sloan Kettering Cancer Center. Recent translational work focuses on epigenetic modifiers, tumor microenvironment modulation, and biomarkers for early transformation detection, with multicenter collaborations spanning Fred Hutchinson Cancer Research Center and Broad Institute.